NEW YORK, Feb 16 – Genaissance Pharmaceuticals has joined the Molecular Simulations’ Functional Genomics consortium, MSI said Friday.

Membership in this consortium gives Genaissance access to MSIs AtlasBase collection of functionally annoted gene sequences from 23 organisms and software that allows it to search this database, said Sue Rodney, manager of investor relations at Pharmacopeia, MSI’s parent company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.